Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2008 1
2011 4
2012 2
2013 3
2014 2
2015 1
2016 2
2017 1
2018 1
2019 4
2020 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Psychopathological disorders in Prader-Willi syndrome.
Guinovart M, Coronas R, Caixàs A. Guinovart M, et al. Endocrinol Diabetes Nutr (Engl Ed). 2019 Nov;66(9):579-587. doi: 10.1016/j.endinu.2019.03.004. Epub 2019 Apr 18. Endocrinol Diabetes Nutr (Engl Ed). 2019. PMID: 31006652 Review. English, Spanish.
Prader-Willi syndrome is a genetic disorder caused by chromosomal changes in segment 15q11-q13 including cognitive, mental, and behavioral symptoms, as well as a specific physical phenotype. Both the most common psychopathological changes (intellectual disability, obsessio …
Prader-Willi syndrome is a genetic disorder caused by chromosomal changes in segment 15q11-q13 including cognitive, mental, and behav …
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Anagnostou E. Anagnostou E. Curr Opin Neurol. 2018 Apr;31(2):119-125. doi: 10.1097/WCO.0000000000000542. Curr Opin Neurol. 2018. PMID: 29389748 Review.
PURPOSE OF REVIEW: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical …
PURPOSE OF REVIEW: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism
Natural Products and Their Therapeutic Effect on Autism Spectrum Disorder.
Deb S, Phukan BC, Dutta A, Paul R, Bhattacharya P, Manivasagam T, Thenmozhi AJ, Babu CS, Essa MM, Borah A. Deb S, et al. Adv Neurobiol. 2020;24:601-614. doi: 10.1007/978-3-030-30402-7_22. Adv Neurobiol. 2020. PMID: 32006376 Review.
Autism is a complex neurodevelopmental disorder that is evident in early childhood and can persist throughout the entire life. ...Special education programs, speech and language therapy, have been employed for the amelioration of behavioral deficits in autism
Autism is a complex neurodevelopmental disorder that is evident in early childhood and can persist throughout the entire life.
Autism Spectrum Disorders and Metabolic Complications of Obesity.
Shedlock K, Susi A, Gorman GH, Hisle-Gorman E, Erdie-Lalena CR, Nylund CM. Shedlock K, et al. J Pediatr. 2016 Nov;178:183-187.e1. doi: 10.1016/j.jpeds.2016.07.055. Epub 2016 Aug 31. J Pediatr. 2016. PMID: 27592097
OBJECTIVES: To assess for an increased risk of obesity, type 2 diabetes mellitus, hypertension, hyperlipidemia, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in children with autism spectrum disorders (ASD). ...In children with ASD, mood stabiliz …
OBJECTIVES: To assess for an increased risk of obesity, type 2 diabetes mellitus, hypertension, hyperlipidemia, and nonalcoholic fatt …
Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors.
Vanwong N, Ngamsamut N, Nuntamool N, Hongkaew Y, Sukprasong R, Puangpetch A, Limsila P, Sukasem C. Vanwong N, et al. Front Pharmacol. 2020 Nov 6;11:565074. doi: 10.3389/fphar.2020.565074. eCollection 2020. Front Pharmacol. 2020. PMID: 33240086 Free PMC article.
Aims: Obesity is a significant problem for patients taking atypical antipsychotics. ...The first aim was to compare the prevalence of overweight and obesity between children and adolescents with autism spectrum disorder (ASD) treated with risper …
Aims: Obesity is a significant problem for patients taking atypical antipsychotics. ...The first aim was to compare the preval …
Developmental-Behavioral Pediatricians' Diagnosis and Coding of Overweight and Obesity in Children with Autism Spectrum Disorder.
Walls M, Curtin C, Phillips S, Eliasziw M, Jackel C, Must A, Bandini L, Broder-Fingert S. Walls M, et al. J Dev Behav Pediatr. 2020 May;41(4):258-264. doi: 10.1097/DBP.0000000000000783. J Dev Behav Pediatr. 2020. PMID: 32040046
OBJECTIVE: The prevalence of obesity in autism spectrum disorder (ASD) is high, and managing obesity in children with ASD can be challenging. ...CONCLUSION: Few children meeting the criteria for overweight/obesity had documented weight-related c …
OBJECTIVE: The prevalence of obesity in autism spectrum disorder (ASD) is high, and managing obesity in children …
Impact of Psychoactive Drug Use on Developing Obesity among Children and Adolescents with Autism Spectrum Diagnosis: A Nested Case-Control Study.
Croteau C, Ben Amor L, Ilies D, Mottron L, Tarride JE, Dorais M, Perreault S. Croteau C, et al. Child Obes. 2019 Feb/Mar;15(2):131-141. doi: 10.1089/chi.2018.0170. Epub 2019 Jan 22. Child Obes. 2019. PMID: 30668140
BACKGROUND: Obesity in children on the autism spectrum (AS) is becoming a significant health concern. The purpose of this study was to identify the predictors of obesity in a cohort of AS youth and to assess the impact of psychoactive medication use while exp …
BACKGROUND: Obesity in children on the autism spectrum (AS) is becoming a significant health concern. The purpose of this stud …
Psychopharmacology of neurobehavioral disorders.
Mooney LN, Dominick KC, Erickson CA. Mooney LN, et al. Handb Clin Neurol. 2019;165:383-390. doi: 10.1016/B978-0-444-64012-3.00023-X. Handb Clin Neurol. 2019. PMID: 31727225 Review.
At times psychotropic drug use is required to address behavioral and other interfering symptoms that accompany neurobehavioral disorders. We review such prescribing practice in autism spectrum disorder, fragile X syndrome, and Prader-Willi syndrome....
At times psychotropic drug use is required to address behavioral and other interfering symptoms that accompany neurobehavioral disorders. We …
Youth-Onset Type 2 Diabetes Manifestations in other Specialties: Its Many Disguises.
Weghuber D, Barrientos-Pérez M, Kovarenko M. Weghuber D, et al. Ann Nutr Metab. 2019;74(4):339-347. doi: 10.1159/000500234. Epub 2019 May 16. Ann Nutr Metab. 2019. PMID: 31096219 Free article. Review.
The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annulare, necrobiosis lipoidica diabeticorum, and scleredema), …
The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to …
29 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page